Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024

Structure Therapeutics Inc.

2024-Q1 EPS reported -$0.19

Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.
Topline GSBR-1290 Phase 2a obesity 12-week data for 40 participants expected June 2024; Phase 2b obesity study to start Q4 2024.
R&D expenses $20.7M (+58% YoY) driven by GLP-1R franchise; G&A expenses $11.3M (+74% YoY) from public company infrastructure.
Plan to initiate first-in-human Phase 1 trial of LTSE-2578 (oral LPA1R antagonist for IPF) in June 2024.
Amylin candidate selection expected Q4 2024; GIPR candidate selection H1 2025; ANPA-0073 (APJR) Phase 1 completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Structure Therapeutics Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 totaled $26.0 million.

Period: first quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 totaled $26.0 million
Result: reported results

Exact text from the filing

Structure Therapeutics Inc. (the "Company") issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-059329

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.